| pubmed-article:8508372 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8508372 | lifeskim:mentions | umls-concept:C0021083 | lld:lifeskim |
| pubmed-article:8508372 | lifeskim:mentions | umls-concept:C0021756 | lld:lifeskim |
| pubmed-article:8508372 | lifeskim:mentions | umls-concept:C0032227 | lld:lifeskim |
| pubmed-article:8508372 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:8508372 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:8508372 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:8508372 | lifeskim:mentions | umls-concept:C0595451 | lld:lifeskim |
| pubmed-article:8508372 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:8508372 | pubmed:dateCreated | 1993-7-9 | lld:pubmed |
| pubmed-article:8508372 | pubmed:abstractText | The authors assessed the tolerance and efficacy of intrapleural interleukin-2 (IL-2) in patients with malignant effusion. | lld:pubmed |
| pubmed-article:8508372 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8508372 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8508372 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8508372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8508372 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8508372 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8508372 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:8508372 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:8508372 | pubmed:author | pubmed-author:ReyFF | lld:pubmed |
| pubmed-article:8508372 | pubmed:author | pubmed-author:ViallatJ RJR | lld:pubmed |
| pubmed-article:8508372 | pubmed:author | pubmed-author:BoutinCC | lld:pubmed |
| pubmed-article:8508372 | pubmed:author | pubmed-author:FarissePP | lld:pubmed |
| pubmed-article:8508372 | pubmed:author | pubmed-author:BrandelyMM | lld:pubmed |
| pubmed-article:8508372 | pubmed:author | pubmed-author:AstoulPP | lld:pubmed |
| pubmed-article:8508372 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8508372 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:8508372 | pubmed:volume | 71 | lld:pubmed |
| pubmed-article:8508372 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8508372 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8508372 | pubmed:pagination | 4067-71 | lld:pubmed |
| pubmed-article:8508372 | pubmed:dateRevised | 2010-3-24 | lld:pubmed |
| pubmed-article:8508372 | pubmed:meshHeading | pubmed-meshheading:8508372-... | lld:pubmed |
| pubmed-article:8508372 | pubmed:meshHeading | pubmed-meshheading:8508372-... | lld:pubmed |
| pubmed-article:8508372 | pubmed:meshHeading | pubmed-meshheading:8508372-... | lld:pubmed |
| pubmed-article:8508372 | pubmed:meshHeading | pubmed-meshheading:8508372-... | lld:pubmed |
| pubmed-article:8508372 | pubmed:meshHeading | pubmed-meshheading:8508372-... | lld:pubmed |
| pubmed-article:8508372 | pubmed:meshHeading | pubmed-meshheading:8508372-... | lld:pubmed |
| pubmed-article:8508372 | pubmed:meshHeading | pubmed-meshheading:8508372-... | lld:pubmed |
| pubmed-article:8508372 | pubmed:meshHeading | pubmed-meshheading:8508372-... | lld:pubmed |
| pubmed-article:8508372 | pubmed:meshHeading | pubmed-meshheading:8508372-... | lld:pubmed |
| pubmed-article:8508372 | pubmed:meshHeading | pubmed-meshheading:8508372-... | lld:pubmed |
| pubmed-article:8508372 | pubmed:meshHeading | pubmed-meshheading:8508372-... | lld:pubmed |
| pubmed-article:8508372 | pubmed:meshHeading | pubmed-meshheading:8508372-... | lld:pubmed |
| pubmed-article:8508372 | pubmed:meshHeading | pubmed-meshheading:8508372-... | lld:pubmed |
| pubmed-article:8508372 | pubmed:meshHeading | pubmed-meshheading:8508372-... | lld:pubmed |
| pubmed-article:8508372 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8508372 | pubmed:articleTitle | Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions. | lld:pubmed |
| pubmed-article:8508372 | pubmed:affiliation | Institut Paoli-Calmettes, Marseille, France. | lld:pubmed |
| pubmed-article:8508372 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8508372 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8508372 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| pubmed-article:8508372 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8508372 | lld:pubmed |
